Ptc Therapeutics, Inc.
A biopharmaceutical company that develops treatments for rare diseases, with medicines including Sephience for PKU, Translarna and Emflaza for Duchenne muscular dystrophy, Evrysdi for spinal muscular atrophy, and the gene therapy Upstaza/Kebilidi. Founded in 1998 by RNA researcher Stuart Peltz, the company's name comes from "post-transcriptional control," the field of RNA biology it was built around.
Granted 48.0K · Sold 26.5K
Granted 393.6K · Sold 104.3K
Granted 354.6K · Sold 324.7K
Granted 187.7K · Sold 161.3K
Granted 64.6K · Bought 7.7K · Sold 12.3K
Granted 61.4K · Sold 23.5K
Granted 81.6K · Sold 51.5K
Granted 355.9K · Sold 364.2K
Granted 56.0K · Sold 44.0K
Granted 24.0K · Sold 12.0K
Granted 24.0K · Sold 12.0K
Granted 12.0K
Granted 60.0K · Sold 50.9K
Granted 23.7K · Sold 11.7K
Granted 79.2K · Sold 75.7K
Granted 4.0K
Granted 27.2K · Sold 26.5K
Granted 7.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Schmertzler MichaelDirector · 10 transactions | — | 1.52M | 48.0K | — | 26.5K |
| Klein Matthew B.CHIEF EXECUTIVE OFFICER, Director · 32 transactions | +283.8% | 394.0K | 393.6K | — | 104.3K |
| Boulding Mark ElliottEXEC. VP AND CLO · 126 transactions | +42.1% | 107.1K | 354.6K | — | 324.7K |
| Pauwels EricCHIEF BUSINESS OFFICER · 69 transactions | +91.3% | 91.0K | 187.7K | — | 161.3K |
| Gravier PierreCHIEF FINANCIAL OFFICER · 11 transactions | +235.8% | 87.3K | 64.6K | 7.7K | 12.3K |
| Golden Lee ScottEVP & CHIEF MEDICAL OFFICER · 19 transactions | +101.4% | 79.1K | 61.4K | — | 23.5K |
| Utter Christine MarieSVP, CHIEF ACCOUNTING OFFICER · 23 transactions | +84.4% | 70.2K | 81.6K | — | 51.5K |
| Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER · 103 transactions | -6.4% | 62.9K | 355.9K | — | 364.2K |
| Zeldis Jerome BDirector · 12 transactions | +114.3% | 22.5K | 56.0K | — | 44.0K |
| Southwell David PDirector · 6 transactions | — | 22.5K | 24.0K | — | 12.0K |
| Steele Glenn Jr MD PHDDirector · 5 transactions | +114.3% | 22.5K | 24.0K | — | 12.0K |
| Smith Mary L.Director · 3 transactions | +122.3% | 21.8K | 12.0K | — | — |
| Jacobson Allan StevenDirector · 23 transactions | -39.3% | 21.5K | 60.0K | — | 50.9K |
| Young AlethiaDirector · 7 transactions | +132.3% | 21.1K | 23.7K | — | 11.7K |
| Reeve EmmaDirector · 32 transactions | +48.1% | 10.7K | 79.2K | — | 75.7K |
| Bell William F. Jr.Director · 1 transaction | +63.2% | 10.3Kas of Feb 2024 | 4.0K | — | — |
| Okey StephanieDirector · 10 transactions | +36.4% | 8.0K | 27.2K | — | 26.5K |
| Chutter Jessica CarolineDirector · 2 transactions | — | 7.3K | 7.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -1.29M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.